<DOC>
	<DOCNO>NCT00916357</DOCNO>
	<brief_summary>This single-center , Phase 2 , randomize , double-blind , 3-way crossover meal study participant Type 2 Diabetes Mellitus ( T2DM ) determine optimum dose compare pharmacokinetics ( PK ) postprandial glycemic response Humalog alone , Humalog + recombinant human hyaluronidase PH20 ( rHuPH20 ) , Humulin-R + rHuPH20 administer subcutaneously .</brief_summary>
	<brief_title>Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 ( rHuPH20 ) Regular Human Insulin With rHuPH20 Compare Pharmacokinetics , Postprandial Glycemic Response , Optimal Insulin Dose Participants With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>This study design choose assess difference pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameter , include postprandial glycemic response , Humalog + recombinant human hyaluronidase PH20 ( rHuPH20 ) , Humalog alone , Humulin-R + rHuPH20 optimal dos follow liquid meal .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Male female age 18 70 year , inclusive Participants Type 2 diabetes mellitus ( T2DM ) per World Health Organization criterion treat basal and/or bolus insulin ≥12 month . Body mass index ( BMI ) 18 45 kilogram per square meter ( kg/m^2 ) , inclusive Glycosylated hemoglobin A1c ( HbA1c ) ≤10 % Current treatment insulin ≥60 Units/day ( U/d ) A participant take oral hypoglycemic agent must stable dose &gt; 8 week exception thiazolidinediones ( TZD ) , &gt; 12 week . Total body weight &gt; 65 kilogram ( kg ) ( 143 pound [ lb ] ) men &gt; 46 kg ( 101 lb ) woman Vital sign ( blood pressure [ BP ] , pulse rate , body temperature ) within normal range , range , assess Investigator clinically significant ( NCS ) Participants good general health base medical history physical examination without medical condition might prevent completion study drug injection assessment protocol Decision make capacity willingness comply schedule visit , treatment plan , laboratory test , study procedure include adequate venous access . Signed write Internal Review Boardapproved inform consent Known suspect allergy component study drug study Previous enrollment study A participant proliferative retinopathy , proliferative maculopathy , and/or severe neuropathy ( particular , autonomic neuropathy ) judge Investigator As judged Investigator , clinically significant active disease gastrointestinal , cardiovascular ( include history arrhythmia conduction delay electrocardiogram [ ECG ] New York Heart Association [ NYHA ] Class III/IV heart disease ) , hepatic , neurological , renal , genitourinary , hematological system As judged Investigator , uncontrolled hypertension ( diastolic BP ≥100 millimeter mercury [ mmHg ] and/or systolic BP ≥160 mmHg 5 minute supine position ) . As judged Investigator , clinically significant finding routine laboratory data ( anemia hematocrit le 33 % screen specifically exclusionary ) Positive human immunodeficiency virus ( HIV ) antibody test , hepatitis B ( antiHBsAg ) , hepatitis C ( antiHCV ) antibody test Current addiction alcohol substance abuse determined Investigator Known use drug ( oral hypoglycemic agent ) may interfere interpretation study result know cause clinically relevant interference insulin action , glucose utilization , recovery hypoglycemia Recurrent major hypoglycemia hypoglycemic unawareness determine Investigator Mental incapacity , unwillingness , language barrier preclude adequate understanding cooperation study Symptomatic gastroparesis Donation blood excess 500 milliliter ( mL ) within 56 day dose Use investigational drug device 30 day enrollment study Pregnancy , breastfeeding , intention become pregnant , use adequate contraceptive measure ( adequate contraceptive measure consist sterilization , intrauterine device [ IUD ] , oral injectable contraceptive , barrier method , remain abstinent ) Any condition ( intrinsic extrinsic ) , judgment Investigator , interfere study participation evaluation data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recombinant human hyaluronidase PH20 ( rHuPH20 )</keyword>
	<keyword>Insulin lispro</keyword>
	<keyword>Regular human insulin</keyword>
</DOC>